High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

Options for patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after brentuximab vedotin (Bv) and autologous stem cell transplantation (ASCT) are limited. Immune checkpoint inhibitors (ICI) are active in this population but rarely induce complete response (CR). Ten patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Falchi, Lorenzo, Sawas, Ahmed, Deng, Changchun, Amengual, Jennifer E., Colbourn, Donald S., Lichtenstein, Emily A., Khan, Karen A., Schwartz, Lawrence H., O’Connor, Owen A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129196/
https://www.ncbi.nlm.nih.gov/pubmed/27899158
http://dx.doi.org/10.1186/s13045-016-0363-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129196/
https://www.ncbi.nlm.nih.gov/pubmed/27899158
http://dx.doi.org/10.1186/s13045-016-0363-1

Ejemplares similares